IT
ITNS.US Itonis Inc
- Market cap
- USD 609K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.
Is ITNS.US undervalued?
Graham numberThe Graham number of Itonis Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Itonis Inc fundamental analysis
No fundamental analysis for Itonis Inc yet.
Itonis Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Itonis Inc
Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was fou…
Full company profileItonis Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Itonis Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 450.00 | 7.67K | 9.12K | 8.68K | 2.47K | 4.43K | 3.05K | 1.80K | 344.00 | 152.69 | - |
| Gross Profit | -509.00 | 3.07K | 3.75K | 3.47K | 636.00 | -32.4K | 780.00 | 1.80K | - | - | - |
| Operating Income | -418K | -62.1K | -71.3K | -60.8K | -47.9K | -69.8K | -8.29K | -38.3K | -9.63K | -11.3K | -14.2K |
| EBITDA | -419K | -62.1K | -71.3K | 111K | 159K | 165K | 221K | -38.3K | -9.63K | -11.3K | -14.2K |
| Net Income | -423K | -385K | -71.8K | -61.0K | -48.5K | -71.4K | -7.57K | -38.3K | -9.63K | -11.3K | -14.2K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 368K | 58.4K | 57.2K | 49.1K | 53.6K | 23.7K | 19.1K | 92.4K | 138K | 136K | 137K |
| Total Liabilities | 894K | 930K | 1.00M | 1.05M | 1.11M | 1.15M | 1.15M | 1.15M | 1.27M | 1.28M | 1.28M |
| Shareholders' Equity | -526K | -871K | -943K | -1.00M | -1.05M | -1.12M | -1.13M | -1.05M | -1.13M | -1.15M | -1.15M |
| Cash & Short-term Investments | 9.69K | 15.2K | 4.95K | 2.10K | 2.15K | 3.50K | 738.00 | 443.00 | 1.76K | 391.70 | 1.32K |
| Total Debt | 652K | 691K | 765K | 817K | 870K | 910K | 910K | 910K | 1.04M | 1.04M | 1.05M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -77.7K | -60.3K | -84.2K | -55.4K | -53.2K | -38.6K | -8.29K | -112K | - | - | -2.51K |
| Capital Expenditure | 0.00 | 13.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | - | - | 0.00 |
| Free Cash Flow | -77.7K | -73.3K | -84.2K | -55.4K | -53.2K | -38.6K | -8.29K | -112K | - | - | -2.51K |
| Ratios | |||||||||||
| ROA | -114.7% | -660.0% | -125.5% | -124.2% | -90.6% | -300.7% | -39.5% | -41.5% | -7.0% | -8.3% | -10.3% |
| Net Profit Margin | -93,934.0% | -5,026.7% | -787.5% | -703.0% | -1,961.4% | -1,612.5% | -248.3% | -2,127.3% | -2,798.8% | -7,415.0% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Itonis Inc dividends
Itonis Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 3:1 on Mar 21, 2007.
Who owns Itonis Inc
Ownership data of Itonis Inc is not available yet.
Itonis Inc company profile
- Company name
- Itonis Inc
- Ticker
- ITNS.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3
- Fiscal year end
- November
- Address
- 22951 Mill Creek Drive, Laguna Hills, CA, United States, 92653
- Phone
- 949-200-8887
- Website
- itonisholdings.com
About Itonis Inc
Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line. The company was formerly known as Kenshou, Inc. and changed its name to Itonis, Inc. in December 2005. Itonis, Inc. was founded in 2005 and is headquartered in Laguna Hills, California.
Itonis Inc management
4- Mr. Mark H. CheungCEO, President & Director
- Dr. Donald L. JollyCFO & Treasurer
- Mr. Corey WashingtonChief Technology Officer
- Dr. Charles B. Hensley Ph.D.President of Itonis Pharmaceuticals